Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells

Vaccine

Volumn 27, Issue 38, 2009, Pages 5239-5246

  Huaman, Maria Cecilia ^a   Mullen, Gregory E D ^a   Long, Carole A ^a   Mahanty, Siddhartha ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Central and effector memory T cells; Multifunctional T cell responses; Plasmodium falciparum apical membrane antigen 1 (PfAMA1)

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; MALARIA VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SAFETY; EFFECTOR CELL; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; NORMAL HUMAN; PATIENT SAFETY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; TH1 CELL; TH2 CELL;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-5; MALARIA VACCINES; MALARIA, FALCIPARUM; MEMBRANE PROTEINS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67651109082     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.066     Document Type: Article

References (44)

1. Rowe A.K., Rowe S.Y., Snow R.W., Korenromp E.L., Schellenberg J.R., Stein C., et al. The burden of malaria mortality among African children in the year 2000. Int J Epidemiol 35 June (3) (2006) 691-704
2. Narum D.L., and Thomas A.W. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol 67 September (1) (1994) 59-68
3. Silvie O., Franetich J.F., Charrin S., Mueller M.S., Siau A., Bodescot M., et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 279 March (10) (2004) 9490-9496
4. Mitchell G.H., Thomas A.W., Margos G., Dluzewski A.R., and Bannister L.H. Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infect Immun 72 January (1) (2004) 154-158
5. Xu H., Hodder A.N., Yan H., Crewther P.E., Anders R.F., and Good M.F. CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. J Immunol 165 July (1) (2000) 389-396
6. Deans J.A., Knight A.M., Jean W.C., Waters A.P., Cohen S., and Mitchell G.H. Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol 10 September (5) (1988) 535-552
7. Cubillos M., Salazar L.M., Torres L., and Patarroyo M.E. Protection against experimental P falciparum malaria is associated with short AMA-1 peptide analogue alpha-helical structures. Biochimie 84 December (12) (2002) 1181-1188
8. Stowers A.W., Kennedy M.C., Keegan B.P., Saul A., Long C.A., and Miller L.H. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 70 December (12) (2002) 6961-6967
9. Remarque E.J., Faber B.W., Kocken C.H., and Thomas A.W. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 24 February (2) (2008) 74-84
10. Narum D.L., Ogun S.A., Thomas A.W., and Holder A.A. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Infect Immun 68 May (5) (2000) 2899-2906
11. Malkin E.M., Diemert D.J., McArthur J.H., Perreault J.R., Miles A.P., Giersing B.K., et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 73 6 (2005) 3677-3685
12. Epstein J.E., Charoenvit Y., Kester K.E., Wang R., Newcomer R., Fitzpatrick S., et al. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine 22 April (13-14) (2004) 1592-1603
13. Peduzzi E., Westerfeld N., Zurbriggen R., Pluschke G., and Daubenberger C.A. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial. Clin Immunol 127 May (2) (2008) 188-197
14. Todryk S.M., Bejon P., Mwangi T., Plebanski M., Urban B., Marsh K., et al. Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS ONE 3 4 (2008) e2027
15. Thompson F.M., Porter D.W., Okitsu S.L., Westerfeld N., Vogel D., Todryk S., et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS ONE 3 1 (2008) e1493
16. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13 July (7) (2007) 843-850
17. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 June (12) (2006) 4781-4789
18. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204 June (6) (2007) 1405-1416
19. Sallusto F., Lenig D., Forster R., Lipp M., and Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401 6754 (1999) 708-712
20. Tan J.T., and Surh C.D. T cell memory. Curr Top Microbiol Immunol 311 (2006) 85-115
21. Mullen G.E., Ellis R.D., Miura K., Malkin E., Nolan C., Hay M., et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS ONE 3 8 (2008) e2940
22. Sandberg J.K., Fast N.M., and Nixon D.F. Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. J Immunol 167 July (1) (2001) 181-187
23. Seder R.A., Darrah P.A., and Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8 April (4) (2008) 247-258
24. Younes S.A., Yassine-Diab B., Dumont A.R., Boulassel M.R., Grossman Z., Routy J.P., et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 198 December (12) (2003) 1909-1922
25. Keating S.M., Bejon P., Berthoud T., Vuola J.M., Todryk S., Webster D.P., et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 175 November (9) (2005) 5675-5680
26. Bejon P., Keating S., Mwacharo J., Kai O.K., Dunachie S., Walther M., et al. Early gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-naive and malaria-exposed individuals. Infect Immun 74 November (11) (2006) 6331-6338
27. Harari A., Vallelian F., Meylan P.R., and Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 174 January (2) (2005) 1037-1045
28. Millington K.A., Innes J.A., Hackforth S., Hinks T.S., Deeks J.J., Dosanjh D.P., et al. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol 178 April (8) (2007) 5217-5226
29. Beveridge N.E., Fletcher H.A., Hughes J., Pathan A.A., Scriba T.J., Minassian A., et al. A comparison of IFNgamma detection methods used in tuberculosis vaccine trials. Tuberculosis (Edinb) 88 November (6) (2008) 631-640
30. Lore K., Adams W.C., Havenga M.J., Precopio M.L., Holterman L., Goudsmit J., et al. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 179 August (3) (2007) 1721-1729
31. Forbes E.K., Sander C., Ronan E.O., McShane H., Hill A.V., Beverley P.C., et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 181 October (7) (2008) 4955-4964
32. Soares A.P., Scriba T.J., Joseph S., Harbacheuski R., Murray R.A., Gelderbloem S.J., et al. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 180 March (5) (2008) 3569-3577
33. Grun J.L., and Maurer P.H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 121 June (1) (1989) 134-145
34. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32 July (3) (1998) 155-172
35. Huaman M.C., Martin L.B., Malkin E., Narum D.L., Miller L.H., Mahanty S., et al. Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers. J Immunol 180 February (3) (2008) 1451-1461
36. Roestenberg M., Remarque E., de Jonge E., Hermsen R., Blythman H., Leroy O., et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS ONE 3 12 (2008) e3960
37. De Rosa S.C., Lu F.X., Yu J., Perfetto S.P., Falloon J., Moser S., et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol 173 9 (2004) 5372-5380
38. Stubbe M., Vanderheyde N., Goldman M., and Marchant A. Antigen-specific central memory CD4+ T lymphocytes produce multiple cytokines and proliferate in vivo in humans. J Immunol 177 December (11) (2006) 8185-8190
39. Wu C.Y., Kirman J.R., Rotte M.J., Davey D.F., Perfetto S.P., Rhee E.G., et al. Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat Immunol 3 September (9) (2002) 852-858
40. Zaph C., Uzonna J., Beverley S.M., and Scott P. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat Med 10 October (10) (2004) 1104-1110
41. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan S.P., Parish I.A., et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199 June (2004) 9-26
42. Antia R., Ganusov V.V., and Ahmed R. The role of models in understanding CD8+ T-cell memory. Nat Rev Immunol 5 February (2) (2005) 101-111
43. Song K., Rabin R.L., Hill B.J., De Rosa S.C., Perfetto S.P., Zhang H.H., et al. Characterization of subsets of CD4+ memory T cells reveals early branched pathways of T cell differentiation in humans. Proc Natl Acad Sci USA 102 May (22) (2005) 7916-7921
44. Cellerai C., Harari A., Vallelian F., Boyman O., and Pantaleo G. Functional and phenotypic characterization of tetanus toxoid-specific human CD4+ T cells following re-immunization. Eur J Immunol 37 April (4) (2007) 1129-1138